CoChat

Amenorrheic Bone Loss1

Open access
Miller, Karen K., Klibanski, Anne · 1999 · The Journal of Clinical Endocrinology & Metabolism
Cited by 95

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

THE ASSOCIATION between postmenopausal estrogen deficiency and osteoporosis has been clearly established for many decades. In addition, congenital disorders causing estrogen deficiency, such as Turner’s syndrome or Kallman’s syndrome, may affect bone mineralization. The deleterious effects of acquired functional estrogen deficiency on bone metabolism in young women has only more recently been recognized. Secondary amenorrhea is a common disorder, and more than 4% of premenopausal women experience episodes of amenorrhea lasting more than 3 months (1). Estrogen deficiency in approximately 55% of these women is attributable to hypothalamic amenorrhea, a state of acquired GnRH dysregulation, including hyperprolactinemia, which induces a state of functional menopause. (2) In addition, premature ovarian failure due to autoimmune disease or secondary to chemotherapy is increasingly diagnosed. The effects of estrogen deficiency on bone are characterized by an acceleration of bone turnover with a disproportionate augmentation of resorption compared with formation (3). Trabecular bone is typically affected more than cortical. Although the precise means by which estrogen deficiency causes increased bone turnover is not known, possible mechanisms include a direct effect on osteoblasts via estrogen receptors (4–7); increased osteoclastic activity due to local bone-resorbing cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor (8–15); and an increased skeletal vulnerability to the effects of PTH (16). This review will focus on the pathophysiology of osteoporosis associated with premenopausal estrogen deficiency in women with secondary amenorrhea (Table 1). Causes of amenorrheic bone loss Causes of amenorrheic bone loss Hyperprolactinemia, excessive exercise, stress, undernutrition, and anorexia nervosa are all causes of functional acquired GnRH deficiency and are associated with osteopenia. Functional GnRH deficiency is characterized by a wide spectrum of disordered GnRH secretion leading ultimately to ovarian dysfunction and deficiency of gonadal steroids. The most prevalent pattern of GnRH secretion, as demonstrated by frequent LH sampling, is a reduced frequency of pulsations (17). However, several other patterns of GnRH pulsatility have been documented and include frank apulsatility, recapitulation of puberty with pulsation occurring at night only (documented in some women with anorexia nervosa), decreased pulse amplitude, and a pattern of pulses seen normally in the early follicular phase (17–19). These disparate pulsatility patterns all result in a lack of folliculogenesis, progression to anovulation, and consequent gonadal steroid deficiencies resulting in osteopenia. In other women with organic sellar or central nervous system disease, including pituitary tumors and radiation damage, structural abnormalities may be present affecting GnRH and/or gonadotropin secretion. Finally, the use of GnRH agonists for the treatment of endometriosis, uterine fibroids, and other disorders has resulted in iatrogenically induced estrogen deficiency. Hyperprolactinemic amenorrhea was the first identified model of functional hypogonadal osteoporosis and is associated with a 17% decrease in cortical (20) and a 15–30% decrease in trabecular (21–23) bone density. The importance of estrogen deficiency in the pathogenesis of bone loss in these young women was demonstrated by Klibanski et al., who showed that spinal bone mass was significantly lower in amenorrheic hyperprolactinemic women than that in their eumenorrheic counterparts despite similar elevations in PRL levels (24). In addition, patients with a longer duration of amenorrhea tend to have lower bone density (25). Factors other than menstrual status also contribute to the pathogenesis of bone loss in this population. As has been suggested in studies of women with premature menopause, obesity may be protective against osteopenia. In one study, a small subgroup of hyperprolactinemic amenorrheic women, 120–125% of ideal body weight, had normal cortical bone density, although their thinner counterparts demonstrated significant bone loss (25). Moreover, a significant correlation between spinal bone density and serum dehydroepiandrosterone sulfate levels has been reported in hyperprolactinemic women and raises the possibility that adrenal androgens play a role in the maintenance of normal bone mass in women (24). If untreated, bone loss progresses in patients with hyperprolactinemic amenorrhea. Biller et al. found that spinal bone density decreased significantly in a group of hyperprolactinemic women who remained amenorrheic over a period of 1.7 ± 0.2 (±sem) yr and resulted in a bone density more than 2 sd below the control mean in 42% of the group. However, restoration of normal menstrual function with dopamine agonist therapy results in an increase in bone density in most, but not all, women treated (Fig. 1) (26). The largest increases in bone density occur dur

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jcem.84.6.5688

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 95

Metadata

Authors
Miller, K. K., & Klibanski, A.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
1999-06
Volume
84
Issue
6
Pages
1775-1783
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2007510934
Cited by
95
References
10
FWCI
7.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amenorrheic Bone Loss1. https://app.cochat.ai/papers/10.1210/jcem.84.6.5688
The paper
Miller, K. K., & Klibanski, A. (1999). Amenorrheic Bone Loss1. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.84.6.5688

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.